Smeenk, R., Van Velthuysen, M., Verwaal, V., et al. (2008). Appendiceal neoplasms and pseudomyxoma peritonei: A population based study. European Journal of Surgical Oncology (EJSO), 34(2), 196–201.
Carr, N. J., Bibeau, F., Bradley, R. F., et al. (2017). The histopathological classification, diagnosis and differential diagnosis of mucinous appendiceal neoplasms, appendiceal adenocarcinomas and pseudomyxoma peritonei. Histopathology, 71(6), 847–858.
Carr, N. J., Cecil, T. D., Mohamed, F., et al. (2016). A consensus for classification and pathologic reporting of pseudomyxoma peritonei and associated appendiceal neoplasia: The results of the Peritoneal Surface Oncology Group International (PSOGI) modified Delphi Process. The American journal of surgical pathology, 40(1), 14–26.
Alakus, H., Babicky, M., Ghosh, P., et al. (2014). Genome-wide mutational analysis reveals core signaling pathways in mucinous neoplasms of the appendix. Cancer Research, 74(19), 1.
Sugarbaker, P. H. (1994). Pseudomyxoma peritonei: A cancer whose biology is characterized by a redistribution phenomenon. Annals of Surgery, 219(2), 109–111.
Bree, E. D., Witkamp, A., Van De Vijver, M., et al. (2000). Unusual origins of pseudomyxoma peritonei. Journal of surgical oncology, 75(4), 270–274.
Ronnett, B. M., Kurman, R. J., Zahn, C. M., et al. (1995). Pseudomyxoma peritonei in women: A clinicopathologic analysis of 30 cases with emphasis on site of origin, prognosis, and relationship to ovarian mucinous tumors of low malignant potential. Human Pathology, 26(5), 509–524.
Young, R. H., Gilks, C. B., & Scully, R. E. (1991). Mucinous tumors of the appendix associated with mucinous tumors of the ovary and pseudomyxoma peritonei. A clinicopathological analysis of 22 cases supporting an origin in the appendix. The American journal of surgical pathology, 15(5), 415–429.
Misdraji, J., Yantiss, R. K., Graeme-Cook, F. M., et al. (2003). Appendiceal mucinous neoplasms: A clinicopathologic analysis of 107 cases. Am J Surg Pathol, 27(8), 1089–1103.
Bradley, R. F., Stewart IV, J. H., Russell, G. B., et al. (2006). Pseudomyxoma peritonei of appendiceal origin: A clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review. The American journal of surgical pathology, 30(5), 551–559.
Sugarbaker, P. H. (2006). New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? The lancet oncology, 7(1), 69–76.
Sugarbaker, P. H. (2001). Cytoreductive surgery and perioperative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome. Tumori Journal, 87(4), 3–5.
Kusamura, S., O’Dwyer, S. T., Baratti, D., et al. (2008). Technical aspects of cytoreductive surgery. Journal of surgical oncology, 98(4), 232–236.
Chua, T. C., Moran, B. J., Sugarbaker, P. H., et al. (2012). Early-and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Journal of Clinical Oncology, 30(20), 2449–2456.
Gusani, N. J., Cho, S. W., Colovos, C., et al. (2008). Aggressive surgical management of peritoneal carcinomatosis with low mortality in a high-volume tertiary cancer center. Annals of Surgical Oncology, 15(3), 754–763.
Miner, T. J., Shia, J., Jaques, D. P., et al. (2005). Long-term survival following treatment of pseudomyxoma peritonei: An analysis of surgical therapy. Annals of Surgery, 241(2), 300.
Sommariva, A., Tonello, M., Rigotto, G., et al. (2021). Novel perspectives in pseudomyxoma peritonei treatment. Cancers (Basel), 13(23), 5965.
Govaerts, K., Lurvink, R. J., De Hingh, I. H. J. T., et al. (2021). Appendiceal tumours and pseudomyxoma peritonei: Literature review with PSOGI/EURACAN clinical practice guidelines for diagnosis and treatment. European Journal of Surgical Oncology, 47(1), 11–35.
Kusamura, S., Barretta, F., Yonemura, Y., et al. (2021). The role of hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei after cytoreductive surgery. JAMA Surg, 156(3), e206363.
Järvinen, P., Ristimäki, A., Kantonen, J., et al. (2013). Feasibility of radical cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei of appendiceal origin. Scandinavian Journal of Surgery, 102(3), 145–151.
Baratti, D., Kusamura, S., Nonaka, D., et al. (2009). Pseudomyxoma peritonei biological features are the dominant prognostic determinants after complete cytoreduction and hyperthermic intraperitoneal chemotherapy. Annals of Surgery, 249(2), 243–249.
Muzny, D. M., Bainbridge, M. N., Chang, K., et al. (2012). Comprehensive molecular characterization of human colon and rectal cancer. Nature, 487(7407), 330–337.
Shukla, H. D. (2017). Comprehensive analysis of cancer-proteogenome to identify biomarkers for the early diagnosis and prognosis of cancer. Proteomes, 5(4), 28.
Tan, A. C., & Tan, D. S. W. (2022). Targeted therapies for lung cancer patients with oncogenic driver molecular alterations. J Clin Oncol, 40(6), 611–625.
Lau, K. H., Tan, A. M., & Shi, Y. (2022). New and emerging targeted therapies for advanced breast cancer. International Journal of Molecular Sciences, 23(4), 2288.
Noguchi, R., Yano, H., Gohda, Y., et al. (2015). Molecular profiles of high-grade and low-grade pseudomyxoma peritonei. Cancer Med, 4(12), 1809–1816.
Stein, A., Strong, E., Clark Gamblin, T., et al. (2020). Molecular and genetic markers in appendiceal mucinous tumors: A systematic review. Annals of Surgical Oncology, 27(1), 85–97.
Moher, D., Liberati, A., Tetzlaff, J., et al. (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS medicine, 6(7), e1000097.
Sterne, J. A., Hernán, M. A., Reeves, B. C., et al. (2016). ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ, 355, i4919.
Flatmark, K., Torgunrud, A., Fleten, K. G., et al. (2021). Peptide vaccine targeting mutated GNAS: a potential novel treatment for pseudomyxoma peritonei. Journal for immunotherapy of cancer, 9(10), e003109.
Moaven, O., Su, J., Jin, G., et al. (2020). Clinical implications of genetic signatures in appendiceal cancer patients with incomplete cytoreduction/HIPEC. Annals of Surgical Oncology, 27(13), 5016–5023.
Liao, X., Vavinskaya, V., Sun, K., et al. (2020). Mutation profile of high-grade appendiceal mucinous neoplasm. Histopathology, 76(3), 461–469.
King, M. C., Munoz-Zuluaga, C., Ledakis, P., et al. (2020). Germline and somatic genetic alterations in two first-degree relatives with appendiceal low-grade mucinous carcinoma peritonei. Clin Case Rep, 8(12), 3168–3177.
Yanai, Y., Saito, T., Hayashi, T., et al. (2020). Molecular and clinicopathological features of appendiceal mucinous neoplasms. Virchows Archiv, 478(3), 413–426.
Foster, J. M., Patel, A., Zhang, C., et al. (2020). Investigating the utility of extended mutation analysis in gastrointestinal peritoneal metastasis. Journal of Surgical Oncology, 122(6), 1106–1113.
Lung, M. S., Mitchell, C. A., Doyle, M. A., et al. (2020). Germline whole exome sequencing of a family with appendiceal mucinous tumours presenting with pseudomyxoma peritonei. BMC Cancer, 20(1), 369.
Su, J., Jin, G. X., Votanopoulos, K. I., et al. (2020). Prognostic molecular classification of appendiceal mucinous neoplasms treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Annals of Surgical Oncology, 27(5), 1439–1447.
Tsai, J. H., Yang, C. Y., Yuan, R. H., et al. (2019). Correlation of molecular and morphological features of appendiceal epithelial neoplasms. Histopathology, 75(4), 468–477.
LaFramboise, W. A., Pai, R. K., Petrosko, P., et al. (2019). Discrimination of low- and high-grade appendiceal mucinous neoplasms by targeted sequencing of cancer-related variants. Mod Pathol, 32(8), 1197–1209.
Liu, W., Liu, L., Wang, R., et al. (2019). Bevacizumab combined with oxaliplatin/capecitabine in patient with refractory and recurrent mucinous adenocarcinoma of the appendix: A case report. Front Oncol, 9, 55.
Tokunaga, R., Xiu, J., Johnston, C., et al. (2019). Molecular profiling of appendiceal adenocarcinoma and comparison with right-sided and left-sided colorectal cancer. Clinical Cancer Research, 25(10), 3096–3103.
Zhu, X., Salhab, M., Tomaszewicz, K., et al. (2019). Heterogeneous mutational profile and prognosis conferred by TP53 mutations in appendiceal mucinous neoplasms. Human Pathology, 85, 260–269.
Ang, C. S., Shen, J. P., Hardy-Abeloos, C. J., et al. (2018). Genomic landscape of appendiceal neoplasms. JCO Precision Oncology, 8(2), 1–18.
Gleeson, E. M., Feldman, R., Mapow, B. L., et al. (2018). Appendix-derived pseudomyxoma peritonei (PMP): Molecular profiling toward treatment of a rare malignancy. American Journal of Clinical Oncology, 41(8), 777–783.
Pengelly, R. J., Rowaiye, B., Pickard, K., et al. (2018). Analysis of mutation and loss of heterozygosity by whole-exome sequencing yields insights into pseudomyxoma peritonei. Journal of Molecular Diagnostics, 20(5), 635–642.
Wen, K. W., Grenert, J. P., Joseph, N. M., et al. (2018). Genomic profile of appendiceal goblet cell carcinoid is distinct compared to appendiceal neuroendocrine tumor and conventional adenocarcinoma. Human Pathology, 77, 166–174.
Ang, C., Stollman, A., Zhu, H., et al. (2017). Clinical benefit from trametinib in a patient with appendiceal adenocarcinoma with a gnas r201h mutation. case rep oncol, 10(2), 548–552.
Matson, D. R., Xu, J., Huffman, L., et al. (2017). KRAS and GNAS Co-mutation in metastatic low-grade appendiceal mucinous neoplasm (LAMN) to the ovaries: A practical role for next-generation sequencing. Am J Case Rep, 18, 558–562.
Saarinen, L., Nummela, P., Thiel, A., et al. (2017). Multiple components of PKA and TGF-β pathways are mutated in pseudomyxoma peritonei. PLoS One, 12(4), e0174898.
Borazanci, E., Millis, S. Z., Kimbrough, J., et al. (2017). Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis. J Gastrointest Oncol, 8(1), 164–172.
留言 (0)